BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Authors » Tamra Sami

Articles by Tamra Sami

Australia builds national innovation database to chart course of new health tech

March 14, 2018
By Tamra Sami
PERTH, Australia – Australia is launching an online "innovation showcase" that aims to catalogue and track the progress of innovations in the pharmaceutical, medical technology and digital health space across Australia in real time on a public platform open to investors, health practitioners and the public.
Read More

J&J, Cook Medical expand Australia operations, cite top-notch science, high demand

March 8, 2018
By Tamra Sami

Australia builds national innovation database to chart course of new health tech

March 8, 2018
By Tamra Sami
PERTH, Australia – Australia is launching an online "innovation showcase" that aims to catalogue and track the progress of innovations in the pharmaceutical, medical technology and digital health space across Australia in real time on a public platform open to investors, health practitioners and the public.
Read More

Australia builds national database to chart the course of new health technology

March 6, 2018
By Tamra Sami

Mesoblast's stem cell therapy meets primary endpoint in phase III GVHD pediatric trial

Feb. 28, 2018
By Tamra Sami
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal stem cell candidate, MSC-100-IV (remestemcel-L), met the primary endpoint in a phase III trial in children with refractory acute graft-vs.-host disease (aGVHD).
Read More

Rhythm Biosciences' blood-based colon cancer test may offer alternative to fecal test

Feb. 26, 2018
By Tamra Sami

Mesoblast's stem cell therapy meets primary endpoint in phase III GVHD pediatric trial

Feb. 23, 2018
By Tamra Sami
PERTH, Australia – Australian stem cell therapy company Mesoblast Ltd. said its allogeneic mesenchymal stem cell candidate, MSC-100-IV (remestemcel-L), met the primary endpoint in a phase III trial in children with refractory acute graft-vs.-host disease (aGVHD).
Read More

Australia's NME approvals fall to five-year low in 2017

Feb. 16, 2018
By Tamra Sami
PERTH, Australia – In 2017, Australia's Therapeutic Goods Administration (TGA) approved the lowest number of new molecular entities since 2012 – just 34, compared to 42 in 2016 and 45 in 2015.
Read More

Admedus expands Cardiocel franchise in India as it builds on emerging markets strategy

Feb. 15, 2018
By Tamra Sami

Allergan pays $95M up front for Australian tissue repair firm Elastagen

Feb. 14, 2018
By Tamra Sami
PERTH, Australia – Allergan plc is acquiring Sydney-based Elastagen Pty Ltd., a private company with a tissue repair platform that complements Allergan's aesthetic and dermatology franchise.
Read More
Previous 1 2 … 197 198 199 200 201 202 203 204 205 … 218 219 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing